David Fajgenbaum: Pioneering the use of agent-based models to revolutionize drug repurposing

David Fajgenbaum shared on X:

”At Every Cure, we are pioneering the use of agent-based models to revolutionize drug repurposing.

We first rank all 3,000 FDA-approved drugs against 22,000 diseases, generating 66 million scores.

After generating initial scores for potential treatments, we are pioneering different large language models (LLMs) to serve in various specialized roles.

One LLM could be trained to focus on safety, another on health equity, and yet another on ethics.

These models then review and debate the scores from their unique perspectives, helping us determine the most promising opportunities to prioritize, validate, and disseminate.

This innovative approach ensures a comprehensive and balanced assessment, leading to more effective and equitable treatments for patients.”

Source: David Fajgenbaum/X

David Fajgenbaum is the co-founder and President of the Castleman Disease Collaborative Network (CDCN), the Founding Director of the Center for Cytokine Storm Treatment and Laboratory (CSTL), Associate Director of Patient Impact for the Penn Orphan Disease Center, and an Associate Professor of Medicine in Translational Medicine and Human Genetics at the University of Pennsylvania. Dr. Fajgenbaum is also the national bestselling author of “Chasing My Cure: A Doctor’s Race to Turn Hope Into Action” and a patient battling idiopathic multicentric Castleman disease (iMCD).